ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements with these filters
Gujarat Kidney and Super Speciality Limited issued a corrigendum to its FY 2025-26 Annual Report. The update includes missing Secretarial Audit observations and management responses.
Gujarat Kidney and Super Speciality Limited has issued a notice for its 7th Annual General Meeting scheduled for September 28, 2026. The meeting will address financial statements, director appointments, and related party transactions.
Gujarat Kidney and Super Speciality Limited filed a revised Annual Report for FY 2025-26. The document also includes the notice for its 7th Annual General Meeting.
Gujarat Kidney & Superspeciality Limited released its Annual Report for FY 2025-26. The report includes the notice for the 7th AGM scheduled for September 28, 2026.
Gujarat Kidney and Super Speciality Ltd appointed Mrs. (Dr) Disha Bharpoda as an Additional Non-Executive Independent Director. The Board also noted shareholder approval for IPO proceeds usage.
Gujarat Kidney And Superspeciality Limited shareholders approved a special resolution via postal ballot. The resolution authorizes variation in the objects/terms of utilization of IPO proceeds.
Gujarat Kidney and Super Speciality Ltd submitted its Regulation 32 statement regarding the utilization of IPO proceeds for the quarter ended June 30, 2026.
Gujarat Kidney and Super Speciality Ltd has appointed Mr. Paresh Dhoti as an Additional Non-Executive Independent Director for a five-year term, effective August 14, 2026.
Gujarat Kidney and Super Speciality Ltd reported revenue from operations of ₹34.3 Cr (+124.2% YoY) and net profit of ₹5.3 Cr (-1.9% YoY) for Q1 FY27.
Gujarat Kidney and Superspeciality Limited has scheduled a Board Meeting for August 14, 2026, to consider quarterly financial results.
Gujarat Kidney and Super Speciality Limited has issued a notice for a postal ballot meeting. Shareholders will vote on varying the objects of IPO proceeds.
Gujarat Kidney corrected an earlier filing, reclassifying the appointment of Mr. Paresh Dhoti as a Non-Executive Non-Independent Director due to pending IICA registration.
Gujarat Kidney and Super Speciality Ltd has filed its quarterly shareholding pattern. The report details holdings for promoters and public shareholders as of June 30, 2026.
Gujarat Kidney and Super Speciality appointed Mr. Paresh Mohanbhai Dhoti as Independent Director. He joins the board for a five-year term effective July 9, 2026.
Gujarat Kidney and Super Speciality acquires 51% of Dubai-based Blue Tree Clinics for ₹19.84 Crore. This expansion diversifies its medical services into the UAE market.
Gujarat Kidney and Super Speciality will acquire a 51% stake in UAE-based Blue Tree Clinics LLC for Rs 19.84 Crore. The acquisition expands operations into Dubai's medical services market.
Gujarat Kidney and Super Speciality Ltd passed a special resolution to vary IPO proceeds utilization. The resolution received 100% approval with 56,894,699 votes in favour.
Gujarat Kidney and Super Speciality Limited appointed Siddharth Shah as Internal Auditor and SPANJ & Associates as Secretarial Auditor. These governance appointments ensure statutory compliance.
Gujarat Kidney and Super Speciality Ltd reported revenue from operations of ₹30.6 Cr (+212.2% YoY) and net profit of ₹4.8 Cr (+220.0% YoY) for Q4 FY26.
Gujarat Kidney and Super Speciality Ltd reported FY26 consolidated revenue of ₹82.89 Crore. Audited financial results were approved at the May 28, 2026 board meeting.
Gujarat Kidney And Super Speciality Limited scheduled a board meeting for May 28, 2026. Directors will consider FY2026 audited financial results and various corporate matters.
Gujarat Kidney And Super Speciality is deploying 100 AI-powered haemodialysis machines across its network. The expansion scales high-tech renal care capacity, starting with Godhra.
Gujarat Kidney And Super Speciality Limited has appointed Mrs. Vishakha Mahesh Phadke as Company Secretary and Compliance Officer, effective April 27, 2026. Mrs. Phadke is an Associate Member of the ICSI with expertise in statutory compliance and corporate governance.
Gujarat Kidney and Super Speciality Limited approved the appointment of Ms. Vishakha Mahesh Phadke as Company Secretary and Compliance Officer. The Board also approved incorporating a ₹0.01 Crore wholly-owned healthcare subsidiary in Bharuch, Gujarat. Additionally, the Board noted shareholder approval for interim IPO fund utilization, financial statement revisions, and secretarial auditor appointment.
Gujarat Kidney And Super Speciality Limited has appointed Mrs. Vishakha Mahesh Phadke as Company Secretary and Compliance Officer, effective April 27, 2026. Mrs. Phadke is an Associate Member of the ICSI with expertise in statutory compliance and corporate governance.
Gujarat Kidney And Super Speciality Limited announced the passing of three resolutions via postal ballot with requisite majority. Approved items include interim fund utilisation for healthcare expansion, voluntary revision of financial statements, and the appointment of Mr. Dharmendra Bhaliya as Secretarial Auditor for FY 2025-26. Voting concluded on April 25, 2026, with the Scrutinizer's report confirming the results.
Gujarat Kidney And Super Speciality Limited paid fines totaling Rs. 20,000 (plus GST) imposed by BSE and NSE. The penalties were for delayed prior intimation regarding a Board of Directors meeting. The company confirmed that these fines have no material impact on its financial or operational activities.
Gujarat Kidney and Super Speciality Ltd paid a total fine of ₹0.002 Crore (Rs. 10,000 each) to BSE and NSE. The penalty was levied for a delay in providing prior intimation regarding a Board of Directors meeting. This settlement resolves the regulatory non-compliance matter.
Gujarat Kidney and Super Speciality Ltd received notices from BSE and NSE imposing a combined fine of ₹0.002 Crore. The penalties relate to delays in furnishing prior intimation for a Board of Directors meeting. The company stated there is no material impact on its financial or operational activities.